Article
Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Nov 2010
Neal Joel W, Heist Rebecca S, Fidias Panos, Temel Jennifer S, Huberman Mark, Marcoux J Paul, Muzikansky Alona, Lynch Thomas J, Sequist Lecia V
Abstract excerpt
INTRODUCTION: Therapeutic agents directed against the epidermal growth factor receptor (EGFR) signaling pathway have been effective in the treatment of non-small cell lung cancer (NSCLC). Cetuximab is a monoclonal antibody against the EGFR receptor with antitumor activity in NSCLC. This study evaluated the efficacy of cetuximab monotherapy after prior treatment with an oral EGFR tyrosine kinase inhibitor (TKI)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.